Insmed Incorporated (NASDAQ:INSM) CEO Sells $1,458,562.50 in Stock

Insmed Incorporated (NASDAQ:INSM - Get Free Report) CEO William Lewis sold 18,750 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $77.79, for a total transaction of $1,458,562.50. Following the transaction, the chief executive officer now owns 334,186 shares in the company, valued at approximately $25,996,328.94. This trade represents a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

William Lewis also recently made the following trade(s):

• On Tuesday, February 18th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $81.03, for a total value of $1,519,312.50.
• On Thursday, February 6th, William Lewis sold 79,350 shares of Insmed stock. The stock was sold at an average price of $80.90, for a total value of $6,419,415.00.
• On Monday, February 3rd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $77.94, for a total value of $1,461,375.00.
• On Wednesday, January 15th, William Lewis sold 31,805 shares of Insmed stock. The stock was sold at an average price of $70.18, for a total value of $2,232,074.90.
• On Friday, January 10th, William Lewis sold 2,978 shares of Insmed stock. The stock was sold at an average price of $63.36, for a total value of $188,686.08.
• On Tuesday, January 7th, William Lewis sold 8,218 shares of Insmed stock. The stock was sold at an average price of $66.02, for a total value of $542,552.36.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.84, for a total value of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.91, for a total value of $1,310,812.50.

Insmed Trading Down 0.2 %

Shares of NASDAQ INSM traded down $0.13 on Friday, reaching $74.89. 1,516,250 shares of the company traded hands, compared to its average volume of 1,981,119. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $84.91. The company has a 50 day moving average of $75.66 and a 200 day moving average of $73.81. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The stock has a market capitalization of $13.56 billion, a PE ratio of -13.40 and a beta of 1.28.

Remove Ads

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The company had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million. On average, equities research analysts forecast that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Royal Bank of Canada assumed coverage on Insmed in a report on Tuesday, February 25th. They issued an "outperform" rating and a $100.00 target price for the company. HC Wainwright reissued a "buy" rating and issued a $90.00 target price on shares of Insmed in a report on Friday, February 21st. Wells Fargo & Company raised their target price on Insmed from $85.00 to $107.00 and gave the company an "overweight" rating in a report on Wednesday, February 19th. Truist Financial raised their target price on Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a report on Friday, February 21st. Finally, Guggenheim restated a "buy" rating and issued a $101.00 price target on shares of Insmed in a research report on Tuesday, February 25th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company's stock. According to MarketBeat, Insmed currently has a consensus rating of "Moderate Buy" and a consensus price target of $93.33.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in Insmed by 6.3% during the 4th quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock worth $1,257,838,000 after purchasing an additional 1,075,796 shares in the last quarter. Darwin Global Management Ltd. increased its position in Insmed by 23.5% during the 4th quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company's stock worth $894,796,000 after purchasing an additional 2,463,261 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in Insmed by 1.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,704,410 shares of the biopharmaceutical company's stock worth $877,113,000 after purchasing an additional 123,429 shares in the last quarter. Capital International Investors increased its position in Insmed by 9.1% during the 4th quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company's stock worth $491,357,000 after purchasing an additional 593,206 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Insmed by 7.2% during the 4th quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company's stock worth $282,243,000 after purchasing an additional 273,759 shares in the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.